Cortical, Spinal, Sacral, and Peripheral Neuromodulations as Therapeutic Approaches for the Treatment of Lower Urinary Tract Symptoms in Multiple Sclerosis Patients: A Review

2021 ◽  
Author(s):  
Martina Pericolini ◽  
Gabriel Miget ◽  
Claire Hentzen ◽  
Enrico Finazzi Agrò ◽  
Camille Chesnel ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Urinary Tract ◽  
Lower Urinary Tract Symptoms ◽  
Lower Urinary Tract ◽  
Therapeutic Approaches ◽  
Urinary Tract Symptoms ◽  
Multiple Sclerosis Patients ◽  
Lower Urinary

scholarly journals Treatment of lower urinary tract symptoms in multiple sclerosis patients: Review of the literature and current guidelines

2017 ◽  
Vol 11 (3-4) ◽  
pp. 110 ◽  
Author(s):  
Shachar Moshe Aharony ◽  
Ornella Lam ◽  
Jacques Corcos
Keyword(s):  
Multiple Sclerosis ◽  
Urinary Tract ◽  
Lower Urinary Tract Symptoms ◽  
Lower Urinary Tract ◽  
Course Evaluation ◽  
Disease Course ◽  
Urinary Tract Symptoms ◽  
Urological Complications ◽  
Multiple Sclerosis Patients ◽  
Lower Urinary

Multiple sclerosis (MS) is a unique neurological disease with a broad spectrum of clinical presentations that are time- and disease course-related. Lower urinary tract symptoms (LUTS) are highly prevalent in this patient population, with approximately 90% showing some degree of voiding dysfunction and/or incontinence 6–8 years after the initial MS diagnosis. Major therapeutic goals include quality of life improvement and the avoidance of urological complications Owing to the wide divergence of clinical symptoms and disease course, evaluation and treatment differ between patients. Treatment must be customized for each patient based on disease phase, patient independence, manual dexterity, social support, and other medical- or MS-related issues. Ablative or irreversible therapies are indicated only when the disease course is stable. In most cases of “safe” bladder, behavioural treatment is considered first-line defense. Antimuscarinic drugs, alone or in combination with intermittent self-catheterization, are currently the mainstay of conservative treatment, and several other medications may help in specific disease conditions. Second-line treatment includes botulinum toxin A injection, neuromodulation, indwelling catheters, and surgery in well-selected cases.

Pharmacotherapeutic management of lower urinary tract symptoms in Multiple Sclerosis patients

2020 ◽  
Vol 21 (12) ◽  
pp. 1449-1454
Author(s):  
Aurora Zanghì ◽  
Sebastiano Cimino ◽  
Daniele Urzì ◽  
Salvatore Privitera ◽  
Francesco Zagari ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Urinary Tract ◽  
Lower Urinary Tract Symptoms ◽  
Lower Urinary Tract ◽  
Urinary Tract Symptoms ◽  
Multiple Sclerosis Patients ◽  
Lower Urinary

scholarly journals Specificity of Lower Urinary Tract Symptoms in Neuromyelitis Optica in Comparison With Multiple Sclerosis Patients

2018 ◽  
Vol 22 (3) ◽  
pp. 185-191
Author(s):  
Arnaud Declemy ◽  
Camille Chesnel ◽  
Audrey Charlanes ◽  
Frederique Le Breton ◽  
Samer Sheikh Ismael ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Urinary Tract ◽  
Lower Urinary Tract Symptoms ◽  
Neuromyelitis Optica ◽  
Lower Urinary Tract ◽  
Urinary Tract Symptoms ◽  
Multiple Sclerosis Patients ◽  
Lower Urinary

scholarly journals Evaluation of lower urinary tract symptoms in multiple sclerosis patients: Review of the literature and current guidelines

2017 ◽  
Vol 11 (1-2) ◽  
pp. 61 ◽  
Author(s):  
Shachar Moshe Aharony ◽  
Ornella Lam ◽  
Jacques Corcos
Keyword(s):  
Multiple Sclerosis ◽  
Urinary Tract ◽  
Lower Urinary Tract Symptoms ◽  
Lower Urinary Tract ◽  
Volume Measurement ◽  
Disease Course ◽  
Clinical Presentations ◽  
Urinary Tract Symptoms ◽  
Multiple Sclerosis Patients ◽  
Lower Urinary

Multiple sclerosis (MS) is a unique neurological disease with a broad spectrum of clinical presentations that are time- and disease course-related. MS plaque location (intracranial and/or spinal) is a key feature in the pathophysiology of disease-related lower urinary tract symptoms (LUTS). The prevalence of these symptoms in MS patients is very high, with nearly 90% of them experiencing some degree of voiding dysfunction and/or incontinence. LUTS rarely present as primary MS manifestations and usually appear 6–8 years after the initial diagnosis. Symptom severity usually correlates with the disability status of patients. Patient assessment comprises clinical and advanced investigations. Each patient should be evaluated uniquely, after taking into account his/her symptoms, disease course and length, comorbidities, physical status, and medications. Basic investigation includes detailed history-taking, physical examination, and post-void residual volume measurement. Advanced evaluation consists of imaging and specific testing, with pivotal importance on urodynamic study.

scholarly journals Surveying the Prevalence of Lower Urinary Tract Symptoms Based on Individual and Clinical Parameters in Patients with Multiple Sclerosis

2019 ◽  
Author(s):  
Fatemeh Nazari ◽  
Vahid Shaygannejad ◽  
Mehrdad Mohammadi Sichani ◽  
Marjan Mansourian Gharaagozlou ◽  
Valiollah Hajhashemi
Keyword(s):  
Multiple Sclerosis ◽  
Urinary Tract ◽  
Symptom Score ◽  
Lower Urinary Tract Symptoms ◽  
Lower Urinary Tract ◽  
Statistical Tests ◽  
Men And Women ◽  
Urinary Tract Symptoms ◽  
Significant Difference ◽  
Lower Urinary

Abstract Background Most patients with multiple sclerosis (MS) suffer from bladder dysfunction during the course of the disease. This study was conducted to examine the prevalence of these complications among patients with MS. Methods This cross-sectional study was performed on 603 patients with MS who referred to the neurology clinics of Kashani and Alzahra Hospitals affiliated to Isfahan University of Medical Sciences, Isfahan, Iran. The sampling was performed by multi-stage random cluster sampling method and the informed consent form was filled in by the subjects. Then, all the data were collected through interviews using the Lower Urinary Tract Symptom Score (LUTSS) developed in accordance with the definitions presented by the International Continence Society (ICS) and the International Prostate Symptom Score (I-PSS). The data were analyzed using descriptive and inferential statistical tests in SPSS and the significance level was considered to be less than 0.050. Results The prevalence rate of lower urinary tract symptoms (LUTS) was 87.6% among all the subjects, with a similar rate among women (88.0%) and men (86.0%). There was a significant difference between the two groups of men and women in terms of the prevalence of stress urinary incontinence (SUI), intermittent urine flow, hesitancy, straining, and dribbling (P < 0.050). There was no significant difference between the two groups of women and men in terms of the prevalence of other symptoms (P > 0.050). Moreover, there was a significant difference between the degree of LUTS with age, marital status, education, duration of illness, clinical course, and disability (P < 0.05). Conclusions A high prevalence of LUTS was found among patients with MS, with similar rates in men and women, and the nature of the urinary complaints and LUTS was different among men and women with MS. Therefore, it is recommended that the health system take necessary measures regarding timely detection and treatment of LUTS among these patients in order to prevent secondary outcomes and improve the quality of life (QOL) of patients with MS.

Barriers experienced by patients with multiple sclerosis in seeking care for lower urinary tract symptoms

2016 ◽  
Vol 36 (4) ◽  
pp. 1208-1213 ◽  
Author(s):  
Benjamin M. Brucker ◽  
Victor W. Nitti ◽  
Sidhartha Kalra ◽  
Joseph Herbert ◽  
Areeba Sadiq ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Urinary Tract ◽  
Lower Urinary Tract Symptoms ◽  
Lower Urinary Tract ◽  
Urinary Tract Symptoms ◽  
Lower Urinary
Sign in / Sign up

Export Citation Format

Share Document